Pro-Pharmaceuticals, Inc. Expands Patent Portfolio with New Patents in the U.S. and Australia

Published: Mar 22, 2011

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, “Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer” in Australia and “Selectively Depolymerized Galactomannan Polysaccharide” in the United States. These are the sixth and seventh patents in Pro-Pharmaceuticals’ growing portfolio that cover its core Galectin-targeting compounds, further reinforcing our intellectual property around the world.

Back to news